Since 1986, when I first got infected with the research bug working with Professor Trevor Redgrave in the Department of Physiology at the University of Western Australia, I have been involved in a wide range of different research studies.
My research involvement covers an in-depth analysis’s of cancer in such areas as cancer epidemiology, molecular biology, cell biology, tumour receptors, biophysics, tracer kinetics, pharmacokinetics, new drug safety, new cancer drug efficacy as well as studies on the mechanism of action of therapeutic agents, and pharma sponsored clinical trials assessing new targeted therapies and new therapeutic regimens.
I have also been heavily involved in research assessing new dementia imaging agents and the impact on brain function of drugs targeting Alzheimer’s. I have also been previously involved in vascular disease research including cardiovascular and cerebrovascular disease research.
Over the last few years I have been fortunate enough to be a contributor to TelixU. TelixU is an innovative platform dedicated to nuclear medicine education and research developed by Telix Pharmaceuticals, an Australian radiopharmaceutical company.
My focus on reader training and case studies aims to enhance the learning experience for healthcare professionals worldwide. By sharing my expertise in molecular imaging, nuclear oncology and other areas of interest, I hope to share my knowledge to expand their skills and ultimately improve patient care.
TelixU’s commitment to advancing the field aligns perfectly with my own, making it a privilege to be involved in such a dynamic and impactful initiative.
Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes
Hanh Nguyen, Kathryn Hird, Joe Cardaci, Steven Smith, Nat P Lenzo
Year Published:
2024
Safety, tolerability, and dosimetry of 177Lu-TLX591 with best standard of care in patients with PSMA-expressing metastatic castration-resistant prostate cancer …
N Lenzo, K O’Byrne, S Ngai, D Meyrick, N Patel, C Hayward Journal of Clinical Oncology 42 (4_suppl), TPS253-TPS253
Year Published:
2024
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic …
Year Published:
2024
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study
Year Published:
2024
Theranostics in Australia: The Importance of Vision and Training, and the Power of Collaboration
N Lenzo
Year Published:
2024
Dr. Nat Lenzo is an experienced medical professional with a diverse educational background with over 25 years experience in general internal medicine and nuclear oncology.